Lentiviral vectors for the preparation of immunotherapeutical compositions
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsPierre Charneau, Huseyin Firat, Veronique Zennou
Life of this patent
Estimating the term…
Loading patent…
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsPierre Charneau, Huseyin Firat, Veronique Zennou
Estimating the term…
The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cellmediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
Immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cellmediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
Immunogenic composition comprising recombinant retroviral particles comprising 1) a recombinant nucleotide sequence containing a defined nucleotide sequence (transgene), placed under the control of regulatory signals of transcription and expression, regulatory signals of retrotranscription, expression and encapsidation and 2) a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like. origin or from a transposon and being inserted in a functional orientation and location with retrotranscription regulatory signals of retroviral or retroviral-like origin or transposons regulatory signals, wherein the immunogenic composition is capable of inducing or of stimulating a cell-mediated response, such as a CTL (Cytotoxic T Lymphocytes) response or a CD4 response against one or several epitopes encoded by the transgene sequence present in the vector.
Immunogenic composition comprising recombinant retroviral vector particles comprising:
Immunogenic composition wherein the recombinant retroviral-like particles comprise:
Vector characterized in that it is the plasmid pTRIP.TEUAML-IRES-EGFP, deposited with the CNCM on Oct. 11, 1999, under number I-2326, or a Ptrip.DES-IRES-GFP deposited with the CNCM on Oct. 11, 1999, under I-2331.
Vector characterized in that it is the plasmid pTRIP.ILKE-IRES-GFP, deposited with the CNCM on Oct. 11, 1999, under number I-2327.
Recombinant vector characterized in that it comprises a polynucleotide containing a cis-acting central initiation region (cPPT) and a cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) which nucleofide sequence is the sequence of a gene of a pathogenic agent, and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
Use of a nucleotidic sequence comprising the cPPT and CTS regions which adopt a threestranded DNA structure (the DNA triplex) after reverse transcription in a lentiviral or retrotransposon vector and stimulates the rate of entry of the vector DNA into the nucleus of the transduced cell.
A three-stranded DNA sequence induced by the cPPT and CTS regions capable of inducing a high rate of entry or increasing the rate of nuclear import of the vector DNA.
Dependencies are inferred from the claim text.